RxDoctor Payments Data

David Castillejos, MD

Ophthalmology · Chula Vista, CANPI 1558446401

Payments from drug & device makers

$2,095in general payments, 2019–2025

Across 83 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$435
  • Biotissue Holdings Inc.$343
  • Alcon$276
  • Amgen$135
  • Novartis$121
  • Regeneron Healthcare Solutions, Inc.$97
  • plus $689 from 16 others

What the payments were for

  • Food & beverage$2,01896%
  • Education$784%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,095 in reported general payments places this provider in the 55th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$240,279
Medicare patients
344
Services billed
1,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost317$167,482
XiidraLifitegrast159$144,829
RestasisCyclosporine68$58,826
Prednisolone Acetate901$52,270
VyzultaLatanoprostene Bunod78$33,408
RhopressaNetarsudil Mesylate87$33,302
Ciprofloxacin Hcl736$17,130
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol98$15,978
Alphagan PBrimonidine Tartrate30$15,855
Brimonidine Tartrate317$15,446
SimbrinzaBrinzolamide/Brimonidine Tart68$14,182
TyrvayaVarenicline Tartrate17$13,560
Diclofenac Sodium844$10,366
MieboPerfluorohexyloctane/Pf12$9,089
Latanoprost757$9,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$435$250,222442 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$83$187,326249 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$66$39,850107 claims
AlconSimbrinza$276$14,18268 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$47$3,76916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →